Information on availability for PERSERIS®

Share

Effective May 31, 2026, Indivior will discontinue availability for PERSERIS® (risperidone) extended-release injectable suspension (90 mg - 120 mg). Indivior has not taken this action due to safety or efficacy issues related to the product.

If you are a Healthcare Provider and have patients currently taking PERSERIS®, please plan to switch your patients to an alternate therapy or modify their treatment plan based on your clinical judgement. After May 31, 2026, it may be possible to obtain PERSERIS® for a few more months depending upon supplier inventory.

If you are a patient currently taking PERSERIS®, please discuss options for alternate treatment with your Healthcare Provider.

Our medical team is available to answer any medical inquiries to PERSERIS you might have. They can be reached at infoMIU@indivior.com or by calling 1-877-782-6966. Also, to report adverse events related to PERSERIS®, please call us at 1-877-782-6966 or email us at: PatientSafetyNA@Indivior.com.

Full prescribing information for PERSERIS® is available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210655s014lbl.pdf 
Thank you for your continued commitment to patient care.


Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Privacy Policy Cookie Notice

Manage Consent Preferences

Always Active